FLT3 and acute myeloid leukemia: The RADIUS trial was a phase II clinical trial randomizing 60 patients with FLT3-ITD AML after allogeneic stem cell transplant to up to 12 4-week cycles of standard of care treatment with or without midostaurin maintenance therapy (11).